Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: NASDAQ:FCSC
- CUSIP: N/A
- Web: www.fibrocell.com
Capitalization:- Market Cap: $36.14 million
- Outstanding Shares: 14,693,000
Average Prices:- 50 Day Moving Avg: $2.10
- 200 Day Moving Avg: $1.25
- 52 Week Range: $1.57 - $7.08
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.26
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $354,999.00
- Price / Sales: 101.82
- Book Value: $0.54 per share
- Price / Book: 4.56
Profitability:- EBIDTA: ($21,510,000.00)
- Net Margins: -7,362.25%
- Return on Equity: -215.38%
- Return on Assets: -105.48%
Debt:- Current Ratio: 8.80%
- Quick Ratio: 8.80%
Misc:- Average Volume: 108,879 shs.
- Beta: 0.51
- Short Ratio: 1.78
Frequently Asked Questions for Fibrocell Science (NASDAQ:FCSC)
What is Fibrocell Science's stock symbol?
Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC."
How were Fibrocell Science's earnings last quarter?
Fibrocell Science Inc (NASDAQ:FCSC) issued its earnings results on Wednesday, May, 10th. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.29. Fibrocell Science had a negative net margin of 7,362.25% and a negative return on equity of 215.38%. View Fibrocell Science's Earnings History.
Where is Fibrocell Science's stock going? Where will Fibrocell Science's stock price be in 2017?
6 analysts have issued 1-year target prices for Fibrocell Science's stock. Their forecasts range from $1.50 to $12.00. On average, they anticipate Fibrocell Science's stock price to reach $4.42 in the next twelve months. View Analyst Ratings for Fibrocell Science.
Who are some of Fibrocell Science's key competitors?
Who owns Fibrocell Science stock?
Fibrocell Science's stock is owned by many different of retail and institutional investors. Top institutional investors include Third Security LLC (37.71%), FMR LLC (5.91%), Vanguard Group Inc. (2.68%), Renaissance Technologies LLC (0.59%), Cambridge Investment Research Advisors Inc. (0.46%) and Geode Capital Management LLC (0.41%). Company insiders that own Fibrocell Science stock include David Pernock and Randal J Kirk. View Institutional Ownership Trends for Fibrocell Science.
Who sold Fibrocell Science stock? Who is selling Fibrocell Science stock?
Fibrocell Science's stock was sold by a variety of institutional investors in the last quarter, including Third Security LLC, FMR LLC, Vanguard Group Inc., Cambridge Investment Research Advisors Inc., Geode Capital Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Fibrocell Science.
How do I buy Fibrocell Science stock?
Shares of Fibrocell Science can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Fibrocell Science stock cost?
One share of Fibrocell Science stock can currently be purchased for approximately $2.46.
Earnings History for Fibrocell Science (NASDAQ:FCSC)Earnings History by Quarter for Fibrocell Science (NASDAQ:FCSC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | ($0.29) | ($0.58) | | | View | N/A |  |
| 11/3/2016 | Q316 | ($0.15) | ($0.05) | $0.07 million | $0.22 million | View | N/A | |
| 3/10/2016 | Q415 | ($0.17) | ($0.40) | $0.07 million | $0.08 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.16) | ($0.07) | $0.06 million | $0.08 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.16) | ($0.17) | $0.09 million | $0.14 million | View | N/A | |
| 5/8/2015 | Q1 2015 | ($0.16) | ($0.17) | $0.05 million | $0.19 million | View | N/A | |
| 3/13/2015 | Q4 2014 | ($0.16) | ($0.16) | $0.06 million | $0.06 million | View | N/A | |
| 11/7/2014 | Q3 14 | ($0.14) | ($0.17) | $0.06 million | $0.02 million | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.18) | ($0.08) | $0.07 million | $0.06 million | View | N/A | |
| 5/19/2014 | Q114 | ($0.15) | ($0.35) | $0.05 million | $0.05 million | View | N/A | |
| 3/17/2014 | Q414 | ($0.26) | ($0.14) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Fibrocell Science (NASDAQ:FCSC)2017 EPS Consensus Estimate: ($0.77)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.31) | ($0.07) | ($0.19) |
| Q2 2017 | 4 | ($0.34) | ($0.07) | ($0.20) |
| Q3 2017 | 4 | ($0.35) | ($0.05) | ($0.20) |
| Q4 2017 | 3 | ($0.37) | ($0.05) | ($0.20) |
(Data provided by Zacks Investment Research)
Dividend History for Fibrocell Science (NASDAQ:FCSC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Fibrocell Science (NASDAQ:FCSC)Insider Ownership Percentage: 1.70%
Institutional Ownership Percentage: 56.34%
Insider Trades by Quarter for Fibrocell Science (NASDAQ:FCSC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/2/2016 | David Pernock | Chairman | Buy | 50,000 | $0.92 | $46,000.00 | |
| 11/13/2015 | David Pernock | CEO | Buy | 3,000 | $5.00 | $15,000.00 | |
| 8/11/2015 | David Pernock | CEO | Buy | 3,500 | $6.54 | $22,890.00 | |
| 7/27/2015 | Randal J Kirk | Major Shareholder | Buy | 975,987 | $5.80 | $5,660,724.60 | |
| 5/13/2015 | David Pernock | CEO | Buy | 16,600 | $4.30 | $71,380.00 | |
| 12/12/2014 | David Pernock | CEO | Buy | 5,000 | $2.52 | $12,600.00 | |
| 11/20/2014 | David Pernock | CEO | Buy | 5,000 | $2.54 | $12,700.00 | |
| 11/20/2014 | John Michael Maslowski | VP | Buy | 1,000 | $2.54 | $2,540.00 | |
| 6/5/2014 | Christine St.Clare | Director | Buy | 10,000 | $3.00 | $30,000.00 | |
| 6/5/2014 | David Pernock | CEO | Buy | 12,500 | $2.95 | $36,875.00 | |
| 6/4/2014 | Kelvin Moore | Director | Buy | 4,557 | $2.99 | $13,625.43 | |
| 6/4/2014 | Randal J Kirk | Major Shareholder | Buy | 400,000 | $2.90 | $1,160,000.00 | |
| 1/24/2014 | Randal J Kirk | Major Shareholder | Buy | 1,024,590 | $4.88 | $4,999,999.20 | |
| 11/21/2013 | David Pernock | CEO | Buy | 10,000 | $3.69 | $36,900.00 | |
| 11/20/2013 | Gregory L Weaver | CFO | Buy | 10,000 | $3.51 | $35,100.00 | |
| 10/1/2013 | Randal J Kirk | Major Shareholder | Buy | 3,658,536 | $4.10 | $14,999,997.60 | |
| 7/26/2013 | Randal J Kirk | Major Shareholder | Buy | 1,243,781 | $6.03 | $7,499,999.43 | |
(Data available from 1/1/2013 forward)
Headline Trends for Fibrocell Science (NASDAQ:FCSC)
Latest Headlines for Fibrocell Science (NASDAQ:FCSC)
| Source: |
|
| Date | Headline |
|---|
 | Brokers Set Expectations for Fibrocell Science Inc's FY2020 Earnings (FCSC)
www.americanbankingnews.com - May 22 at 11:00 AM |
 | Fibrocell Science's (FCSC) CEO John Maslowski on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:44 PM |
| Fibrocell Science Inc (FCSC) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 9:00 PM |
 | Intrexon (XON) Q1 Loss Wider than Expected, Revenues Beat
www.zacks.com - May 11 at 5:46 PM |
 | Investor Network: Fibrocell Science, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 10:18 PM |
 | Fibrocell Science reports 1Q loss
marketbeat.com - May 10 at 8:33 AM |
| Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
finance.yahoo.com - May 9 at 9:27 AM |
 | Fibrocell Science (FCSC) Announces DSMB Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of RDEB
www.streetinsider.com - May 8 at 9:03 AM |
| -$0.29 EPS Expected for Fibrocell Science Inc (FCSC) This Quarter
www.americanbankingnews.com - May 5 at 4:20 PM |
| Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 3 at 8:17 AM |
| Fibrocell Science Inc (FCSC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 1 at 2:48 PM |
| Fibrocell Science (FCSC) Receives News Sentiment Score of 0.33
www.americanbankingnews.com - April 16 at 1:25 PM |
| Zacks: Analysts Expect Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 14 at 4:30 PM |
| Fibrocell Science (FCSC) Receives Daily Media Impact Rating of 0.09
www.americanbankingnews.com - April 13 at 7:00 PM |
 | Fibrocell Science Inc. (FCSC) Has Climbed To A 1-Month High
www.rttnews.com - April 13 at 11:14 AM |
| ETFs with exposure to Fibrocell Science, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:06 PM |
| Fibrocell Science (FCSC) Announces Compliance with NASDAQ Listing Requirements
www.streetinsider.com - March 28 at 11:50 AM |
| Q1 2017 EPS Estimates for Fibrocell Science Inc (FCSC) Boosted by Griffin Securities
www.americanbankingnews.com - March 22 at 9:46 AM |
| FY2020 EPS Estimates for Fibrocell Science Inc (FCSC) Reduced by Analyst
www.americanbankingnews.com - March 21 at 12:22 PM |
| FIBROCELL SCIENCE, INC. Financials
finance.yahoo.com - March 15 at 5:32 PM |
| Fibrocell Science Inc (FCSC) Coverage Initiated at Rodman & Renshaw
www.americanbankingnews.com - March 13 at 2:48 PM |
| Fibrocell Science (FCSC) Plans 1-for-3 Reverse Stock Split
www.streetinsider.com - March 10 at 11:18 AM |
 | Fibrocell Announces One-for-Three Reverse Stock Split
us.rd.yahoo.com - March 10 at 11:18 AM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articl
biz.yahoo.com - March 10 at 11:18 AM |
| Q4 2016 Fibrocell Science Inc Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 5:38 PM |
| Fibrocell Reports 2016 Financial Results and Recent Operational Highlights
finance.yahoo.com - March 9 at 5:38 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
biz.yahoo.com - March 9 at 5:38 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Fin
biz.yahoo.com - March 8 at 5:58 PM |
 | Benzinga's Top Upgrades, Downgrades For March 7, 2017 - Benzinga
www.benzinga.com - March 8 at 8:05 AM |
| 4:55 pm Fibrocell Science entered into securities purchase agreement with existing investors for sale of $8.0 mln Series A Convertible Preferred Stock and accompanying warrants
us.rd.yahoo.com - March 7 at 11:11 PM |
| Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational Highlights
finance.yahoo.com - March 7 at 11:11 PM |
| Coverage initiated on Fibrocell Science by Rodman & Renshaw
finance.yahoo.com - March 7 at 4:59 PM |
| Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million
finance.yahoo.com - March 7 at 4:59 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
biz.yahoo.com - March 3 at 11:50 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
us.rd.yahoo.com - March 1 at 9:54 PM |
| Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
us.rd.yahoo.com - February 23 at 5:11 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 13 at 9:38 AM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 9 at 5:59 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 9 at 5:59 PM |
| Fibrocell Science (FCSC) Receives FDA Fast Track Designation of FCX-007 for Treatment of RDEB - StreetInsider.com
www.streetinsider.com - January 7 at 6:32 PM |
 | Fibrocell Science Receives Fast Track Designation For FCX-007, Shares Up 29% By Mid-Day - Baystreet.ca
www.baystreet.ca - January 7 at 3:48 AM |
| Fibrocell Science Receives Fast Track Designation For FCX-007, Shares Up 29% By Mid-Day
www.baystreet.ca - January 5 at 11:04 PM |
| Fibrocell Science (FCSC) Receives FDA Fast Track Designation of FCX-007 for Treatment of RDEB
www.streetinsider.com - January 5 at 11:04 PM |
| 8:01 am Fibrocell Science announces FDA fast track designation of FCX-007 for treatment of recessive dystrophic epidermolysis bullosa
finance.yahoo.com - January 5 at 6:03 PM |
| FIBROCELL SCIENCE, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 5 at 6:03 PM |
Fibrocell Science (FCSC) Chart for Wednesday, May, 24, 2017
